マツオカ　カツヨシ   Matsuoka Katsuyoshi   松岡　克善    所属   東邦大学  医学部 医学科（佐倉病院）    職種   教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study.
掲載誌名	正式名：BMJ open ISSNコード：20446055
掲載区分	国外
巻・号・頁	12,pp.e060081-1892
著者・共著者	Matsuoka K, Nagano K, Nagasaki S, Murata Y, Hisamatsu T
担当区分	筆頭著者
発行年月	2022/05
概要	INTRODUCTION: Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease of the large intestine. Ustekinumab is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23 and has proven efficacy in inducing and maintaining remission in adult patients with moderate-to-severe UC. In the Symptom Improvement of ulceRative colitis after an Induction dose of Ustekinumab study, we will document the initial treatment response (daily patient-reported outcomes for 8 weeks from first infusion) and treatment patterns of patients wih UC receiving an induction dose of ustekinumab in the real-world setting in Japan. We will also investigate the relationship between the treatment response at week 8 and early indicators of response and determine patient factors that may define the appropriate dosing interval for maintenance therapy. METHODS AND ANALYSIS: For this single-arm, prospective observational study at 24 centres in Japan with a follow-up period of 16/20 weeks, we aim to recruit 140 patients with moderate-to-severe UC between July 2021 and July 2022. All surveys will be conducted in Japanese and patient-reported outcomes relating to rectal bleeding, stool frequency, abdominal pain, nocturnal diarrhoea, tenesmus and perception of UC symptoms will be recorded using a smartphone application, where the patients can enter their initial response to ustekinumab induction therapy on a daily basis. Dosing intervals and the reasons for selecting this interval, and concomitant medications taken during treatment with ustekinumab will be collected by a physician questionnaire at the end of the study. On completion of primary end point (8-week patient-reported outcomes) data collection, results will be reported sequentially. ETHICS AND DISSEMINATION: The study has been approved by the ethics committee of each facility involved and the Institutional Review Board of the non-profit organisation MINS. TRIAL REGISTRATION NUMBER: UMIN000043753, NCT04963725.